SCHEMBL6038443

SCHEMBL6038443

Cc1ccc(S(=O)(=O)Nc2ncc(-c3ccc(OCc4ccccc4)cc3)nc2OCc2cccnc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.54
ADAMTS4 O75173 1/20 0.51
HTT P42858 1/20 0.48
CCR4 P51679 1/20 0.47
POLB P06746 1/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
PKM P14618 1/20 0.44
LMNA P02545 3/20 0.44
ALDH1A1 P00352 2/20 0.43
TP53 P04637 1/20 0.43
KCNA5 P22460 2/20 0.43
PIR O00625 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038479 0.94 POLB (0.49) ARADAMTS4HTTCCR4POLB
SCHEMBL6038816 0.94 CCR4 (0.50) ARADAMTS4HTTCCR4POLB
SCHEMBL6038813 0.94 CCR4 (0.52) ARADAMTS4HTTCCR4POLB
SCHEMBL6038387 0.92 CCR4 (0.47) ARADAMTS4HTTCCR4POLB
SCHEMBL6038916 0.90 CCR4 (0.49) ADAMTS4HTTCCR4POLBKDM4E
SCHEMBL6038775 0.90 CCR4 (0.47) ARADAMTS4HTTCCR4POLB
SCHEMBL6038885 0.89 CCR4 (0.52) ADAMTS4HTTCCR4POLBKDM4E
SCHEMBL6038493 0.89 CCR4 (0.48) ARADAMTS4HTTCCR4POLB
SCHEMBL6039130 0.89 CCR4 (0.48) ADAMTS4HTTCCR4POLBKDM4E
SCHEMBL6038789 0.89 CCR4 (0.46) ADAMTS4HTTCCR4POLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 AR 422/4885ADAMTS4 389/4885HTT 3895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.